

Breast Cancer Treatment: New Developments and New Decisions

Hyman B. Muss, MD

**Lineberger Comprehensive
Cancer Center
University of North Carolina**



UNC


LINEBERGER COMPREHENSIVE
CANCER CENTER
NC CANCER HOSPITAL

Treatment Issues

- Types of breast cancer
- Staging and biology
- Basics of therapy
 - Surgical oncology
 - Radiation oncology
 - Medical oncology
- The “team” approach

Breast Cancer and Age

United States SEER 1997-2001



Types of Breast Cancer

- Ductal carcinoma *in situ* (DCIS)
 - Noninvasive breast cancer
 - Rarely spreads (1-2%)
- Invasive breast cancer
 - Risk of spread varies by stage/biology

Tumor Stage: the Basics

- Based on size, node status and spread
 - The TNM system
- Stages I, II, III – non-metastatic (local or regional) and curable
 - e.g. – breast, axillary lymph node.
- Stage IV – metastatic
 - growth anywhere else
 - e.g. - bone, lymph node, local area, lung or pleura, liver, brain, ovary.

Tumor Staging/Biology = Prognosis

- Distant metastases (M) – trump all else if present, otherwise:
- Tumor size (T)
- Axillary node involvement (N)
- Histology
- Tumor Grade
- Hormone Receptors: Estrogen Progesterone
- HER-2 (human epidermal growth factor receptor) status: gene amplified or not

10 Year Survival by Stage Surgery Only

<u>Stage</u>	<u>%</u>	<u>Definition</u>	<u>10 yr Survival</u>
0	20	In situ	98%
1	50	No nodes	60-95%
2	20	Positive nodes	10-60%
3	5	Large tumor	5-60%
4	5	Metastatic	5-10%

Treatment: Surgery

- Modified radical mastectomy
 - Breast, pectoral fascia, lower axillary lymph nodes

OR

- Breast conservation
 - Lumpectomy with nodal assessment
 - Radiation therapy

MASTECTOMY

1 IN 8

YOUR CHANCES OF GETTING BREAST CANCER

Breast Cancer Striking Younger Than Ever

YOUR BREASTS: NOT JUST FOR LOOKS

BREAST CANCER EPIDEMIC: What's Behind It?

PROFILE OF A KILLER

BREAST CANCER QUIZ: Are You At Risk?



More information and breast self-exams you doing about breast cancer? www.breastcancerfund.org






Breast Conservation = Mastectomy (conservation is lumpectomy/radiation (L/RT))

% Disease-free

% Without Mets

% Alive



Squares = mast., triangles=L/no RT, dark triangles = L/RT
Fisher B et al. NEJM 2002

Radiation Therapy

- Lumpectomy
 - alone - 30% recur, most same area
 - Radiation standard of care
 - Less than 10% recur in breast
- Mastectomy – controversial role
 - large tumors, many + lymph nodes
- Palliation
 - Bone, CNS, some other mets

Systemic Therapy

- Chemotherapy (numerous)
- Hormone therapy (block, lower estrogen)
 - Tamoxifen, oophorectomy, aromatase inhibitors, etc.
- Bisphosphonates for bone mets
- Biologic therapy
 - Trastuzumab (Herceptin) – anti HER-2 antibody
 - Lapatinib (Tykerb) – anti HER-2 small molecule
 - Bevacizumab (Avastin) – anti VEGF antibody

Adjuvant Therapy

The use of chemotherapy, hormone therapy and/or radiation therapy either before or after surgery. The aim is to destroy microscopic metastases that may be present and if left untreated will eventually lead to relapse.

Systemic Therapy: Adjuvant

- **At diagnosis – reduces recurrence (25-50%) and improves survival**
- **Known options:**
 - **Chemotherapy**
 - **Hormone therapy (if ER or PR +)**
 - **Anti HER2 drug trastuzumab (if HER2 +)**
 - **Combinations of these**
- **Considered in all but smallest Stage I tumors**

Adjuvant Therapy: Proportional Reduction

Assume 100 pts, "Cure" 30%, 10 yr follow

Primary Tumor (Mo)	10 yr Survival No Rx	10 yr Survival Rx	Lives saved
1 cm, N-	90%	93%	3
2 cm, 10+ LN	20%	44%	24

Math: 90% cure without Rx means 10% will not survive. 30% of 10% is 3% or three lives saved of 100 pts treated.


Selecting Adjuvant Therapy

- Size, grade and lymph node status
- Hormone Receptors
 - Estrogen and Progesterone Receptors
 - Positive in 60% of patients
 - If not present, hormone Rx does not work
- HER-2
 - Positive in 20% of patients
 - If negative Herceptin does not work

Long Term Impact of Adjuvant Chemo

34% reduction
in relapse risk

26% reduction
in risk of death





Bonadonna G et al. NEJM 1995

Metastatic Disease

- All therapy is palliative
- Median survival depends on tempo not Rx
 - Median is 24 month for all patients
 - About 20% live 5 years and some 20 years
- Goal of Treatment
 - Control of disease and symptoms
 - Maximizing quality of life
- Endocrine Rx → Chemotherapy
 - Single sequential Rx best for most

Bone Metastases: Response



Rx Preference vs Added Survival

McQuellon et al, J Clin Oncol 13:858 '95


% of patients who would elect Rx for:

	<u>1 mth</u>	<u>6 mth</u>	<u>1 yr</u>	<u>5 yr</u>
std chemo	18	44	63	91
phase II	17	33	57	87
hormonal Rx	61	82	93	98
high-dose	9	34	64	100

“Team” Approach

- Multidisciplinary Clinic
 - Face to face, videoconference
- The Team – facilitated by “navigator”
 - Surgery
 - Radiation Oncology
 - Medical Oncology
 - Pathology
 - Genetics
 - Support Program

**UK and USA 1950–2003/2: Females
Breast cancer mortality at ages 35–69**



*Mean of annual rates in the seven component 5-year age groups

Source: WHO mortality & UN population estimates

Summary

- Treatment is complicated and costly
- Team approach best
- Many decisions along the way
 - Lumpectomy vs Mastectomy
 - Radiation
 - Systemic Therapy (Chemo, Endocrine)
- Follow-up essential
- Survivorship issues -lifelong management



Thank You !